MYH10

Across TCGA pan-cancer cohorts, MYH10 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MYH10 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MYH10 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MYH10 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where MYH10 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.300	0.572	<.001	46	view →
CCRCC	DFS	Median	II,III,IV	0.451	1.000	.008	46	view →
LUAD	OS	Median	All	0.854	0.649	.007	12	view →
UCEC	OS	Quartile	II,III,IV	0.520	1.000	.035	4	view →
HNSC	DFS	Median	III,IV	0.937	1.000	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MYH10–PDAC (DFS)

Open the PDAC breakdown →